AI assistant
Sending…
RECURSION PHARMACEUTICALS, INC. — Director's Dealing 2026
Feb 20, 2026
31628_dirs_2026-02-19_975ad73b-eb36-4c55-8ddb-0854f7a98054.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK: 0001601830
Period of Report: 2026-02-17
Reporting Person: Hallett David (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-17 | Class A Common Stock | F | 11908 | $3.49 | Disposed | 1097151 | Direct |
Footnotes
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
More from RECURSION PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 25
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 18
Regulatory Filings
2026
Mar 17
Director's Dealing
2026
Mar 4
Annual Report
2026
Feb 25
Regulatory Filings
2026
Feb 25
Director's Dealing
2026
Feb 20